Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT06930703

Cannabidiol in Sickle Cell Disease

Led by Icahn School of Medicine at Mount Sinai · Updated on 2025-06-25

52

Participants Needed

1

Research Sites

95 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

CONDITIONS

Official Title

Cannabidiol in Sickle Cell Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age >18 years
  • Clinical diagnosis of sickle cell disease (HbSS, HbSC, HbS\u03b2+ Thal, HbS\u03b20Thal, HbS variants)
  • Baseline score of 60 or lower on the ASCQ-Me 7-day pain interference domain
  • Stable dose of sickle cell modifying therapy (hydroxyurea, regular blood transfusions, L-glutamine, voxelotor, crizanlizumab) for at least 3 months if applicable
  • Stable opioid pain medication dose at home for at least 3 months if applicable
  • One urine toxicology negative for cannabinoids within 30 days of randomization
  • Willing to abstain from cannabis, medical and illicit, during study weeks 1 through 4
  • Not pregnant or nursing
  • If a woman capable of becoming pregnant, willing to use a medically accepted form of birth control during study participation
  • Able to consent for research
Not Eligible

You will not qualify if you...

  • Known intolerance to cannabinoids
  • History of psychotic episode, psychosis, or active suicidality
  • Contraindication to epidiolex based on side effects, medications, or medical problems as evaluated by a physician
  • Daily cannabis user
  • Diagnosis of active substance use disorder
  • ALT levels greater than 3 times the upper limit of normal

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Icahn School of Medicine at Mount Sinai

Manhattan, New York, United States, 10029

Actively Recruiting

Loading map...

Research Team

S

Susanna Curtis

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here